Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Breaks Below 200 Day Moving Average – Time to Sell?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)’s stock price passed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $4.03 and traded as low as $4.00. Oramed Pharmaceuticals shares last traded at $4.00, with a volume of 97,260 shares changing hands.

Analyst Ratings Changes

A number of analysts recently weighed in on ORMP shares. Weiss Ratings raised shares of Oramed Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, October 23rd. Wall Street Zen raised Oramed Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. One analyst has rated the stock with a Buy rating. According to MarketBeat.com, Oramed Pharmaceuticals presently has a consensus rating of “Buy”.

Oramed Pharmaceuticals Trading Down 2.7%

The company has a 50-day simple moving average of $4.55 and a 200 day simple moving average of $4.03. The company has a market cap of $166.40 million, a P/E ratio of 0.97 and a beta of 1.29.

Oramed Pharmaceuticals (NASDAQ:ORMP) last released its earnings results on Monday, August 10th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.52). On average, equities analysts forecast that Oramed Pharmaceuticals Inc. will post 1.47 EPS for the current fiscal year.

Insider Activity

In other Oramed Pharmaceuticals news, CFO Avraham Gabay sold 20,000 shares of the business’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $4.51, for a total value of $90,200.00. Following the completion of the sale, the chief financial officer directly owned 861,076 shares of the company’s stock, valued at $3,883,452.76. The trade was a 2.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Joshua Hexter sold 30,000 shares of the company’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $4.51, for a total transaction of $135,300.00. Following the completion of the transaction, the chief operating officer owned 1,328,130 shares in the company, valued at $5,989,866.30. This represents a 2.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Engineers Gate Manager LP purchased a new position in shares of Oramed Pharmaceuticals during the second quarter valued at $61,000. Bank of New York Mellon Corp purchased a new stake in Oramed Pharmaceuticals in the second quarter worth about $381,000. Bank of America Corp DE lifted its stake in Oramed Pharmaceuticals by 2.7% in the first quarter. Bank of America Corp DE now owns 146,152 shares of the biotechnology company’s stock worth $497,000 after acquiring an additional 3,909 shares during the period. OMERS ADMINISTRATION Corp purchased a new stake in Oramed Pharmaceuticals in the first quarter worth about $63,000. Finally, Dimensional Fund Advisors LP grew its holdings in Oramed Pharmaceuticals by 5.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company’s stock worth $538,000 after acquiring an additional 7,738 shares in the last quarter. 12.73% of the stock is currently owned by hedge funds and other institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc (NASDAQ: ORMP) is a biopharmaceutical company focused on developing oral formulations of drugs that are typically administered by injection. The company’s proprietary Protein Oral Delivery (POD™) technology is designed to protect therapeutic proteins from degradation in the digestive system and facilitate their absorption through the gastrointestinal tract.

Oramed’s development programs have primarily focused on oral insulin, including its investigational ORMD-0801 product candidate for the treatment of diabetes.